Kymriah’s Sales Continue to Grow; Novartis Q1 2021 Earnings Call Summary
On Tuesday, April 27, Novartis held their Q1 2021 earnings presentation (press release / presentation) highlighting Kymriah’s continued growth. Of note, no major clinical or regulatory updates were reported. Below, Celltelligence provides its latest US ATC count and insights on how Novartis’s expanding ATC footprint could have facilitated Kymriah’s continued sales growth compared to key competitor Gilead (Kite).
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.